239 related articles for article (PubMed ID: 38584858)
1. Microbiota-Based Therapeutics as New Standard-of-Care Treatment for Recurrent
Stallhofer J; Steube A; Katzer K; Stallmach A
Visc Med; 2024 Apr; 40(2):82-91. PubMed ID: 38584858
[TBL] [Abstract][Full Text] [Related]
2. Microbiota restoration therapies for recurrent
DuPont HL; DuPont AW; Tillotson GS
Therap Adv Gastroenterol; 2024; 17():17562848241253089. PubMed ID: 38800353
[TBL] [Abstract][Full Text] [Related]
3. Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile).
Minkoff NZ; Aslam S; Medina M; Tanner-Smith EE; Zackular JP; Acra S; Nicholson MR; Imdad A
Cochrane Database Syst Rev; 2023 Apr; 4(4):CD013871. PubMed ID: 37096495
[TBL] [Abstract][Full Text] [Related]
4. The role of the gut microbiome in colonization resistance and recurrent
Seekatz AM; Safdar N; Khanna S
Therap Adv Gastroenterol; 2022; 15():17562848221134396. PubMed ID: 36425405
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
Khanna S; Assi M; Lee C; Yoho D; Louie T; Knapple W; Aguilar H; Garcia-Diaz J; Wang GP; Berry SM; Marion J; Su X; Braun T; Bancke L; Feuerstadt P
Drugs; 2022 Oct; 82(15):1527-1538. PubMed ID: 36287379
[TBL] [Abstract][Full Text] [Related]
6. Update on microbiota-derived therapies for recurrent Clostridioides difficile infections.
Benech N; Barbut F; Fitzpatrick F; Krutova M; Davies K; Druart C; Cordaillat-Simmons M; Heritage J; Guery B; Kuijper E;
Clin Microbiol Infect; 2024 Apr; 30(4):462-468. PubMed ID: 38101472
[TBL] [Abstract][Full Text] [Related]
7. Faecal microbiota transplantation in the treatment of recurrent intestinal Clostridioides difficile infection - a ten-year single-center experience.
Pipek B; Valentová H; Fojtík P; Urban O
Cas Lek Cesk; 2022; 161(3-4):126-130. PubMed ID: 36100450
[TBL] [Abstract][Full Text] [Related]
8. The Role of Microbiome-Based Therapeutics in Clostridioides difficile Infection: Durable, Long-Term Results of RBX2660.
Orenstein R
Infect Dis Ther; 2023 Jan; 12(1):1-7. PubMed ID: 36342653
[TBL] [Abstract][Full Text] [Related]
9. Microbiome therapeutics for the treatment of recurrent
Bloom PP; Young VB
Expert Opin Biol Ther; 2023 Jan; 23(1):89-101. PubMed ID: 36536532
[TBL] [Abstract][Full Text] [Related]
10. Long-term durability and safety of fecal microbiota transplantation for recurrent or refractory Clostridioides difficile infection with or without antibiotic exposure.
Lee CH; Chai J; Hammond K; Jeon SR; Patel Y; Goldeh C; Kim P
Eur J Clin Microbiol Infect Dis; 2019 Sep; 38(9):1731-1735. PubMed ID: 31165961
[TBL] [Abstract][Full Text] [Related]
11. Live Biotherapeutic Products for the Prevention of Recurrent
Pettit NN; Shaeer KM; Chahine EB
Ann Pharmacother; 2024 Mar; ():10600280241239685. PubMed ID: 38546138
[TBL] [Abstract][Full Text] [Related]
12. Advancing therapeutics for recurrent clostridioides difficile infections: an overview of vowst's FDA approval and implications.
Jain N; Umar TP; Fahner AF; Gibietis V
Gut Microbes; 2023; 15(1):2232137. PubMed ID: 37431860
[TBL] [Abstract][Full Text] [Related]
13. Fecal microbiota transplantation for treatment of patients with recurrent
Voth E; Khanna S
Expert Rev Anti Infect Ther; 2020 Jul; 18(7):669-676. PubMed ID: 32266848
[TBL] [Abstract][Full Text] [Related]
14. Fecal Microbiota Transplantation Increases Colonic IL-25 and Dampens Tissue Inflammation in Patients with Recurrent Clostridioides difficile.
Jan N; Hays RA; Oakland DN; Kumar P; Ramakrishnan G; Behm BW; Petri WA; Marie C
mSphere; 2021 Oct; 6(5):e0066921. PubMed ID: 34704776
[TBL] [Abstract][Full Text] [Related]
15. Fecal Microbiota Transplantation and Microbial Therapeutics for the Treatment of Clostridioides difficile Infection in Pediatric Patients.
Bernard R; Hourigan SK; Nicholson MR
J Pediatric Infect Dis Soc; 2021 Nov; 10(Supplement_3):S58-S63. PubMed ID: 34791396
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides difficile Infection in the USA.
Lodise T; Guo A; Yang M; Cook EE; Song W; Yang D; Wang Q; Zhao A; Bochan M
Adv Ther; 2023 Jun; 40(6):2784-2800. PubMed ID: 37093359
[TBL] [Abstract][Full Text] [Related]
17. Gram-Negative Taxa and Antimicrobial Susceptibility after Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection.
Steed DB; Wang T; Raheja D; Waldman AD; Babiker A; Dhere T; Kraft CS; Woodworth MH
mSphere; 2020 Oct; 5(5):. PubMed ID: 33055258
[TBL] [Abstract][Full Text] [Related]
18. SER-109 (VOWST
Blair HA
Drugs; 2024 Mar; 84(3):329-336. PubMed ID: 38441806
[TBL] [Abstract][Full Text] [Related]
19. Fecal microbiota transplantation for recurrent
Sandhu A; Chopra T
Therap Adv Gastroenterol; 2021; 14():17562848211053105. PubMed ID: 34992678
[No Abstract] [Full Text] [Related]
20. Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial.
Orenstein R; Dubberke ER; Khanna S; Lee CH; Yoho D; Johnson S; Hecht G; DuPont HL; Gerding DN; Blount KF; Mische S; Harvey A
BMC Infect Dis; 2022 Mar; 22(1):245. PubMed ID: 35279084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
